SCHEMBL22358090

SCHEMBL22358090

Cc1nn(C)c2cc(-c3noc(C4CCN(C(=O)C5CC(=O)N(c6ccccn6)C5)CC4)n3)ccc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GRM5 P41594 14/20 0.41
▸ ALDH1A1 P00352 2/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.40
▸ KDM4E B2RXH2 1/20 0.40
▸ LMNA P02545 1/20 0.40
▸ TP53 P04637 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ HTT P42858 1/20 0.40
▸ HSD17B10 Q99714 1/20 0.40
▸ POLB P06746 1/20 0.40
▸ HSD11B1 P28845 2/20 0.39
▸ EPHX2 P34913 1/20 0.39
▸ TUBB4A P04350 1/20 0.39
▸ TUBB P07437 1/20 0.39
▸ TUBA3C P0DPH7 1/20 0.39
▸ TUBA1B P68363 1/20 0.39
▸ TUBA4A P68366 1/20 0.39
▸ TUBB4B P68371 1/20 0.39
▸ TUBB3 Q13509 1/20 0.39
▸ TUBB2A Q13885 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22358226 0.91 GRM5 (0.42) GRM5ALDH1A1SMN1; SMN2MAPTPOLB
SCHEMBL22357847 0.91 GRM5 (0.42) GRM5ALDH1A1SMN1; SMN2MAPTPOLB
SCHEMBL22357808 0.91 GRM5 (0.42) GRM5ALDH1A1SMN1; SMN2MAPTPOLB
SCHEMBL22358125 0.91 GRM5 (0.43) GRM5ALDH1A1SMN1; SMN2POLBTUBB4A
SCHEMBL20116104 0.90 GRM5 (0.47) GRM5SMN1; SMN2HSD11B1TUBB4ATUBB
SCHEMBL20116103 0.90 GRM5 (0.47) GRM5SMN1; SMN2HSD11B1TUBB4ATUBB
SCHEMBL30506241 0.90 GRM5 (0.47) GRM5SMN1; SMN2HSD11B1TUBB4ATUBB
SCHEMBL20116106 0.90 GRM5 (0.47) GRM5SMN1; SMN2HSD11B1TUBB4ATUBB
SCHEMBL30506344 0.90 GRM5 (0.47) GRM5SMN1; SMN2HSD11B1TUBB4ATUBB
SCHEMBL22357841 0.90 GRM5 (0.40) GRM5ALDH1A1SMN1; SMN2LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11873298-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2024-01-16 — — US disclosed
US-11873298-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2024-01-16 — — US disclosed
US-20200262828-A1 COMPOUNDS AND USES THEREOF JANSSEN PHARMACEUTICA NV (BE) 2020-08-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11873298-B2 Compounds and uses thereof NLN, ACHE, CLN6 GRM5 68/4885ALDH1A1 656/4885SMN1; SMN2 13/4885
US-20200262828-A1 COMPOUNDS AND USES THEREOF NLN, ACHE, CLN6 GRM5 68/4885ALDH1A1 656/4885SMN1; SMN2 13/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback